A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Status: Recruiting
Location: See all (10) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• RRMM with prior exposure to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD38) monoclonal antibody.
• Measurable disease defined as at least 1 of the following:
‣ Serum M-protein ≥0.5 grams/deciliter
⁃ Urine M-protein ≥200 milligrams (mg)/24-hour
⁃ Involved free light chain (FLC) ≥100 mg/liter and an abnormal FLC ratio
⁃ Plasmacytoma with a single diameter ≥2 centimeters
⁃ Bone marrow plasma cells \>30%
Locations
United States
Alabama
University of Alabama at Birmingham Hospital
NOT_YET_RECRUITING
Birmingham
California
UCSF
NOT_YET_RECRUITING
San Francisco
Georgia
Emory University Hospital
NOT_YET_RECRUITING
Atlanta
Massachusetts
Mass General Brigham
NOT_YET_RECRUITING
Boston
North Carolina
Atrium Health Levine Cancer Institute
NOT_YET_RECRUITING
Charlotte
New York
Memorial Sloan-Kettering Cancer Center
NOT_YET_RECRUITING
New York
Tisch Cancer Institute at Mount Sinai
NOT_YET_RECRUITING
New York
Pennsylvania
Penn Medicine
NOT_YET_RECRUITING
Philadelphia
Tennessee
Sarah Cannon Research Institute
RECRUITING
Nashville
Wisconsin
The Medical College of Wisconsin
NOT_YET_RECRUITING
Milwaukee
Contact Information
Primary
Moderna WeCare Team
WeCareClinicalTrials@modernatx.com
+1-866-663-3762
Time Frame
Start Date: 2025-09-30
Estimated Completion Date: 2032-06-17
Participants
Target number of participants: 166
Treatments
Experimental: mRNA-2808
Participants will receive mRNA-2808.
Related Therapeutic Areas
Sponsors
Leads: ModernaTX, Inc.